ARHGEF3

Across TCGA pan-cancer cohorts, ARHGEF3 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ARHGEF3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ARHGEF3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGEF3 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

HNSC, PDAC, and LUAD are the cancer types where ARHGEF3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	−0.643	<.001	11	view →
PDAC	All	II,III,IV	−0.596	<.001	7	view →
LUAD	All	II,III,IV	−0.170	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

ARHGEF3–HNSC

Open the HNSC breakdown →